Paclitaxel polymeric micelles

Phase 2

SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Paclitaxel polymeric micelles is one of 40 therapeutic programs targeting Head and Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Head and Neck CancerRecruiting

Head and Neck CancerPhase 2

Recruiting

Competition

Competitive Landscape

44 competitors in Head and Neck Cancer

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Keytruda

Merck & Co.

Phase 3

18 3

Erbitux

IImclone

Phase 3

45 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

62 5

Neurontin

VViatris Specialty LLC

Approved

4 6

Oxycontin

PProtega

Approved

2 7

Opdivo

Bristol-Myers Squibb

Phase 3

10 8

Tylenol

KKenvue Brands

Approved

1 9

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 10

Marcaine

IInnocoll

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

SCLC, Recurrent

NCT07819591

Q3 2029

Phase 2Recruiting

Head and Neck Cancer

NCT07662746

Clinical

Trials by Indication[1]

SCLC, Recurrent1 trial

A Phase II Study of Paclitaxel Polymeric Micelles Combined With Ivonescimab in Patients With Recurrent or Refractory Small Cell Lung Cancer After Failure of Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Therapy

Not yet recruiting·SShaodong Hong·Phase 2·NCT07819591·47 enrolled

Head and Neck Cancer1 trial

Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Single-Arm, Exploratory Phase II Clinical Study

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07662746·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Paclitaxel polymeric micelles. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Paclitaxel polymeric micelles. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Paclitaxel polymeric micelles

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

SCLC, Recurrent1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News